$Veru Inc(VERU.US)$ MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA. Presentation details: Advanc...
Watch this one for a pop. they released news of going into phase 2 trials right at post market close. Veru Enrolls First Patients In Phase 2b Clini - moomoo -- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medic...
$Veru Inc(VERU.US)$VERU has rallied 64.5% over the past four weeks, and the company is a #2 (Buy) on the Zacks Rank at the moment. This combination indicates VERU could be poised for a breakout. The bullish case only gets stronger once investors take into account VERU's positive earnings outlook for the current quarter The bullish case only gets stronger once investors take into account VERU's positive earnings outlook for the current quarter. There have been 1 upwards revisions compared to no...
Veru Inc股票討論區
long read
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.
Presentation details:
Advanc...
Pop early IMO..
Veru Enrolls First Patients In Phase 2b Clini - moomoo
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States --
-- Topline clinical data expected in the fourth quarter calendar year 2024 --
MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medic...
The bullish case only gets stronger once investors take into account VERU's positive earnings outlook for the current quarter. There have been 1 upwards revisions compared to no...
Tomorrows watch list for me
$SNDL Inc(SNDL.US)$
$坎伯蘭藥業(CPIX.US)$
$Sonoma Pharmaceuticals(SNOA.US)$
$霧麻科技(ISPR.US)$
$Veru Inc(VERU.US)$
$Greenlane(GNLN.US)$
$OrganiGram(OGI.US)$
$Cronos Group(CRON.US)$
$GrowGeneration(GRWG.US)$
...
NEWS
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
暫無評論